HCW Biologics Inc. reported that on June 18, 2025, Armistice Capital fully exercised pre-funded warrants, purchasing a total of 54,000 shares of the company's common stock, completing the exercise of 513,140 shares originally granted. This follows a previous exercise of 459,140 shares on an earlier date.